Clinical trial
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV)…
NCT00239681 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00239681 |
|---|---|
| Title | JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events |
| Official title | A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Elevated High-sensitivity C-Reactive Protein (hsCRP) |
| Intervention type | Drug, Other |
| Interventions | Rosuvastatin, Placebo |
| Enrollment | 17,802 |
| Start date | Feb 1, 2003 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Oct 17, 2005 |
| Last update posted | Mar 24, 2014 |
| Countries | Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Denmark, El Salvador, Estonia, Germany and 15 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: